Search PubMed⌕ Search

PubMed · 8900338

Estrogen replacement therapy.

Abstract

For decades, observers have noted that women lose their natural resistance to coronary disease following menopause. It is now known that this increase in coronary risk is due to the loss of the protective effect of estrogen. Although still somewhat controversial, estrogen replacement therapy appears to offer significant cardioprotective benefits to postmenopausal women. These benefits extend to women with a history of coronary artery disease as well as to those without. The exact mechanism by which estrogen confers protection is not known, although the primary focus has been on estrogen's effect on serum lipids. Estrogen reduces total cholesterol levels and low-density-lipoprotein cholesterol levels and increases levels of high-density lipoproteins. Recent data suggest that estrogen may also have a beneficial effect on lipoprotein (a), a less studied lipid fraction, and may affect lipid metabolism in the blood-vessel wall. Numerous studies are under way to define better the risks and benefits of estrogen replacement therapy. Until more is known, the decision to recommend estrogen replacement therapy must be made on an individual basis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J M Sullivan. 1996-10-08. Estrogen replacement therapy.. https://doi.org/10.1016/s0002-9343(96)00321-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗